NGX267, a selective cholinergic muscarinic, or M1, receptor agonist, has demonstrated potential in providing both symptomatic improvement and disease modification in animal models of Alzheimer’s disease. This second
Patients were evaluated while receiving either placebo or one of three dose levels of arimoclomol three times daily for 12 weeks and during a 4-week follow-up period without
CDA (chlorproguanil hydrochloride-dapsone-artesunate) is being developed as a fixed-dose combination to meet the urgent need for new malaria treatments in the developing world where multi-drug resistance is contributing
Consequently, the company said that it will not include an FTC approval condition in the formal tender offer it intends to file with the Croatian Financial Services Supervisory
The interim analysis demonstrated a clear positive trend toward efficacy, with 61% (33 of 54) of patients receiving RSD1235 completing the study with normal heart rhythm, as compared
The Nexavar approval is specifically for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon- alpha or interleukin-2 based therapy or are considered
After studying ten patients who suffered heart failure after taking the drug at University of Texas’ M.D. Anderson Cancer Center, the researchers found that a protein targeted by
This clinical trial is designed to assess the safety of TG-C in patients who have opted for total knee arthroplasty. TissueGene has developed TG-C to regenerate cartilage in
Tysabri was removed form the market following its original 2004 approval after it was shown to increase the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection
Symbicort, which is already approved in Europe, is a twice-daily asthma therapy combining budesonide, an inhaled corticosteroid, and formoterol, a rapid and long-acting beta2-agonist into one inhaler. AstraZeneca
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.